544 related articles for article (PubMed ID: 34091054)
1. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs.
Tombácz I; Laczkó D; Shahnawaz H; Muramatsu H; Natesan A; Yadegari A; Papp TE; Alameh MG; Shuvaev V; Mui BL; Tam YK; Muzykantov V; Pardi N; Weissman D; Parhiz H
Mol Ther; 2021 Nov; 29(11):3293-3304. PubMed ID: 34091054
[TBL] [Abstract][Full Text] [Related]
2. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift.
Kheirolomoom A; Kare AJ; Ingham ES; Paulmurugan R; Robinson ER; Baikoghli M; Inayathullah M; Seo JW; Wang J; Fite BZ; Wu B; Tumbale SK; Raie MN; Cheng RH; Nichols L; Borowsky AD; Ferrara KW
Biomaterials; 2022 Feb; 281():121339. PubMed ID: 35078042
[TBL] [Abstract][Full Text] [Related]
3. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.
Vadovics M; Muramatsu H; Sárközy A; Pardi N
Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394
[TBL] [Abstract][Full Text] [Related]
4. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
Qiu M; Li Y; Bloomer H; Xu Q
Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
[TBL] [Abstract][Full Text] [Related]
5. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
7. An Ionizable Lipid Material with a Vitamin E Scaffold as an mRNA Vaccine Platform for Efficient Cytotoxic T Cell Responses.
Oyama R; Ishigame H; Tanaka H; Tateshita N; Itazawa M; Imai R; Nishiumi N; Kishikawa JI; Kato T; Anindita J; Nishikawa Y; Maeki M; Tokeshi M; Tange K; Nakai Y; Sakurai Y; Okada T; Akita H
ACS Nano; 2023 Oct; 17(19):18758-18774. PubMed ID: 37814788
[TBL] [Abstract][Full Text] [Related]
8. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
[TBL] [Abstract][Full Text] [Related]
9. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
Pardi N; Tuyishime S; Muramatsu H; Kariko K; Mui BL; Tam YK; Madden TD; Hope MJ; Weissman D
J Control Release; 2015 Nov; 217():345-51. PubMed ID: 26264835
[TBL] [Abstract][Full Text] [Related]
10. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S
Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637
[TBL] [Abstract][Full Text] [Related]
11. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab.
Jarzebska NT; Frei J; Mellett M; Kündig TM; Pascolo S; Reichmuth AM
Methods Mol Biol; 2024; 2786():237-254. PubMed ID: 38814398
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines.
Li Z; Zhang XQ; Ho W; Li F; Gao M; Bai X; Xu X
ACS Nano; 2022 Nov; 16(11):18936-18950. PubMed ID: 36269150
[TBL] [Abstract][Full Text] [Related]
13. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
Takanashi A; Pouton CW; Al-Wassiti H
Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
[TBL] [Abstract][Full Text] [Related]
14. Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery.
Sun M; Dang UJ; Yuan Y; Psaras AM; Osipitan O; Brooks TA; Lu F; Di Pasqua AJ
AAPS PharmSciTech; 2022 May; 23(5):135. PubMed ID: 35534697
[TBL] [Abstract][Full Text] [Related]
15. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA).
Álvarez-Benedicto E; Farbiak L; Márquez Ramírez M; Wang X; Johnson LT; Mian O; Guerrero ED; Siegwart DJ
Biomater Sci; 2022 Jan; 10(2):549-559. PubMed ID: 34904974
[TBL] [Abstract][Full Text] [Related]
16. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
[TBL] [Abstract][Full Text] [Related]
17. mRNA-Loaded Lipid Nanoparticles Targeting Immune Cells in the Spleen for Use as Cancer Vaccines.
Shimosakai R; Khalil IA; Kimura S; Harashima H
Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015165
[TBL] [Abstract][Full Text] [Related]
18. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis.
Qiu M; Tang Y; Chen J; Muriph R; Ye Z; Huang C; Evans J; Henske EP; Xu Q
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35173043
[TBL] [Abstract][Full Text] [Related]
19. Future considerations for the mRNA-lipid nanoparticle vaccine platform.
Igyártó BZ; Jacobsen S; Ndeupen S
Curr Opin Virol; 2021 Jun; 48():65-72. PubMed ID: 33906124
[TBL] [Abstract][Full Text] [Related]
20. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells.
Patel SK; Billingsley MM; Frazee C; Han X; Swingle KL; Qin J; Alameh MG; Wang K; Weissman D; Mitchell MJ
J Control Release; 2022 Jul; 347():521-532. PubMed ID: 35569584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
